NASDAQ · Biotechnology

EXOZ (EXOZ) Stock

$7.09 +4.26% NASDAQ: EXOZ Healthcare

Valuation

MetricValue
Price$7.09
Market Cap$65.80M
P/E Ratio-5.67
P/B Ratio16.12
P/S Ratio0.00
EPS (TTM)$-1.09
52-Week High$18.40
52-Week Low$4.35
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-292.13%
ROA-127.67%
ROCE-165.90%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.30
Current Ratio2.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-1.0M$-1.0M$-2.0M$-6.0M$-10.0M
Net Profit$-1.0M$-1.0M$-2.0M$-6.0M$-9.0M
EPS$-0.15$-0.17$-0.25$-0.72$-1.09
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$2.0M$3.0M$4.0M$13.0M$6.0M
Total Liabilities$1.0M$1.0M$4.0M$3.0M$3.0M
Cash$1.0M$1.0M$0$10.0M$3.0M
Borrowings$1.0M$1.0M$2.0M$1.0M$1.0M

Latest News

Q2 Virtual Investor Summit Presentations Now Available On Demand ACCESS Newswire · Jun 30, 2026 eXoZymes Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discovery ACCESS Newswire · Jun 24, 2026 Q2 Investor Summit Virtual Live Wednesday June 24 ACCESS Newswire · Jun 23, 2026 eXoZymes Inc. Announces Closing of $6 Million Public Offering ACCESS Newswire · Jun 17, 2026 EXoZymes Prices $5.3 Million Offering MT Newswires · Jun 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-2.0M$-1.0M$-1.0M$-9.0M$-7.0M
Investing Cash Flow$-1.0M$0$-1.0M$-1.0M$0
Financing Cash Flow$0$0$1.0M$0$0
Net Cash Flow$0$0$0$10.0M$-7.0M
Free Cash Flow$-2.0M$-1.0M$-1.0M$-9.0M$-7.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.93
EV / EBITDA-5.53
FCF Yield-11.31%
Quick Ratio3.81
Interest Coverage0.00
Return 1Y-38.18%
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ANEBAnebulo Pharmaceuticals, Inc. $0.34 +0.00% -1.73 $13.72M 0.00%
ATOS $2.53 -0.79% -0.58 $25.24M 0.00%
CGTXCognition Therapeutics, Inc. $1.05 +0.00% -3.94 $93.97M 0.00%
ESLA $0.69 +8.00% -2.80 $29.54M 0.00%
GLSI $15.49 -0.90% -10.15 $227.37M 0.00%

About EXOZ

EXOZ is led by CEO Michael Heltzen, employs 31 people, headquartered in US, publicly traded since 2024.

EXOZ stock trades at $7.09 with a market capitalization of $65.80M. The stock is valued at a price-to-earnings (P/E) ratio of -5.67, price-to-book of 16.12, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $4.35 and $18.40, and currently trades 61.5% below its 52-week high.

On profitability, EXOZ generates a return on equity (ROE) of -292.13%, return on capital employed of -165.90%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1142.62 -1.46% JNJ Drug Manufacturers - General $276.38 -0.74% ABBV Drug Manufacturers - General $257.40 -1.08% MRK Drug Manufacturers - General $150.84 -0.98% UNH Medical - Healthcare Plans $396.99 -0.99% NVS Drug Manufacturers - General $160.37 -1.67% AZN Drug Manufacturers - General $162.56 -1.34% AMGN Drug Manufacturers - General $438.25 -1.32% TMO Medical - Diagnostics & Research $612.47 -0.96% NVO Biotechnology $46.53 -2.07% ABT Medical - Devices $109.46 +0.62% GILD Drug Manufacturers - General $150.64 -0.38%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides